3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
2
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Gastrointestinal Neoplasms
1
CLDN18.2-positive Gastric Adenocarcinoma
1
Ascites
1
Adenocarcinoma
1
Interventions
Oxaliplatin
30
Gemcitabine
28
Fluorouracil
27
Capecitabine
22
Leucovorin
19
pembrolizumab
15
130-nm albumin-bound paclitaxel
13
Irinotecan
12
Cisplatin
11
Bevacizumab
11
Albumin-Bound Paclitaxel
11
Paclitaxel
10
Ramucirumab
8
Radiotherapy
8
Docetaxel
8
Nivolumab
7
trastuzumab deruxtecan
6
Cyclophosphamide
6
Taxes
5
Drug Therapy
5
durvalumab
4
Trastuzumab
4
Metformin
4
zolbetuximab
3
spartalizumab
3
folfirinox
3
cemiplimab
3
XELOX
3
Surgical Procedures, Operative
3
Sorafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
Zoledronic Acid
×
Gastrointestinal
×
Clear all
NCT06759064
2025-11-19
IPIZA
Qilu Hospital of Shandong University
Phase 1/2
Recruiting
24 enrolled